Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, +21

Blood

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

Gábor Kovács, Sandra Robrecht, Anna Maria Fink, +16

Journal of Clinical Oncology

COVID-19 in patients with hematologic malignancy

Petra Langerbeins, Michael Hallek

Blood

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, +43

Blood

Poor efficacy and tolerability of <scp>R‐CHOP</scp> in relapsed/refractory chronic lymphocytic leukemia and <scp>R</scp>ichter transformation

Petra Langerbeins, Raymonde Busch, Nadine Anheier, +12

American Journal of Hematology

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Paula Cramer, Julia von Tresckow, Jasmin Bahlo, +18

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunology +6

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Petra Langerbeins, Can Zhang, Sandra Robrecht, +21

Blood

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Carmen Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, +24

Leukemia

Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL

Christian Maurer, Petra Langerbeins, Jasmin Bahlo, +14

Leukemia

Hematological MalignancySecond Primary MalignanciesMedicineMalignant Blood DisorderHematology +7

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, +19

Leukemia

Clinical Infectious DiseaseCovid-19 PandemicImmunologyAntiviral TherapyChronic Viral Infection +5